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Satranidazole, 1-methylsulphonyl-3-(1-methyl-5-nitro-2-imidazolyl)-2-imidazolidinone, is one of the large series of nitroimidazoles with potent antiprotozoal activity against E. hystolytica, T.vaginalis and giardia [1] . It is not offi cial as yet in IP, USP and BP [2, 3] . Though the molecule is found to be effective against these microorganisms, its therapeutic efficacy is hindered due to its poor aqueous solubility [4] . The poor aqueous solubility and wettability of satranidazole gives rise to diffi culties in pharmaceutical formulations meant for oral or parenteral use, which may lead to variation in bioavailability [5] . Co-solvency is one of the methods to improve solubility especially in case of liquid formulations. The choice of the appropriate co-solvent is important to obtain maximum solubility of drug [6] . Evaluation of solubility parameter in different solvent blends of various polarities would provide important insight about the solubility of drug. Solubility parameter () is an intrinsic physicochemical property that infl uences structure activity and transport kinetics of a drug substance [7] . Literature survey revealed that solubility parameter of satranidazole is not estimated by any method till date. So the present study attempts to determine the solubility parameter of satranidazole in different blends of dioxane-water. Experimental values obtained were compared with the theoretical values obtained by molar volume method and Fedor's group substitution method [8] . Dioxane and water were selected based on their Hildebrand values. Water and dioxane exhibit extremities of polarity [9] . Experimental determination of solubility parameter was based upon the maximum solubility of satranidazole in cosolvent-water blends. For most of cases, 1,4-dioxane and water were chosen as miscible solvent blends, which provides the two extremes of solubility parameters (δ 1 ) 10 and 23.4 (Cal/cm 3 ) 0.5 , respectively. Binary solvent system was prepared by using dioxane and water, ranging from 0% to 100%, respectively, in screw capped vials. The final volume of binary solvent system was kept constant at 2 ml. A slight excess quantity of satranidazole was introduced into each vial and these were shaken for 3 h by keeping on rotary shaker at constant speed at 150 rpm followed by saturation equilibration for 24 h at room temperature (~ 25 o ). Preliminary studies showed that this time was suffi cient to ensure saturation equilibrium [10] . After equilibrium was reached, solutions were filtered through Whatman fi lter paper No. 41 and analyzed after appropriate dilutions with double distilled water by UV Spectrophotometer at 319.80 nm (λ max ). All experimental results are expressed as the average of at least three determinations. The coeffi cient of variation (SD/mean×100) was within 2% among replicated samples for the solubility measurements.
Solubility parameter determination of satranidazole (δ 2 ) was achieved using the solubility measurement method (experimental method) and by theoretical methods, namely, molar volume method and by Fedor's group substitution method proposed by Fedor [11] . In solubility measurement method, the solubility parameter of satranidazole is assumed to be similar to that of the solubility parameter of the solvent (δ 1 ) in which the drug exhibits maximum solubility [12] . Hence, the solubility data (Table 1 ) obtained by the method described in preceding section was used to determine δ 2 .
The solubility parameter of satranidazole was determined by molar volume method by calculating the mole fraction solubility (X 2 ) of satranidazole in solvent blends containing water and dioxane in different ratios as shown in Table 1 . The mole fraction solubility was calculated by using the equation, mole fraction solubility, X 2 =η 2 / η 1 +η 2 (1), where η 1 and η 2 are the number of moles of solvent and solute respectively. A plot of mole fraction solubility of satranidazole in the various ratios of the binary mixtures was made against Δ δ (δ 1 -δ 2 ), difference between solubility parameter of solvent and solute respectively. The solubility parameter of the solvent blend (δ 1 ) in which satranidazole showed peak mole fraction solubility represents the solubility parameter of satranidazole (δ 2 ) [13] .
Fedor's group substitution method is based on the determination of solubility parameter of satranidazole (δ 2 ) by using the Eqn. δ = (∆ u/ ∆ V) 0.5 (2) , in which ∆ u represents the substituent fragment constant and ∆ V represents the fragmental molar volume constant. Further, the solubility parameter of Satranidazole was determined by dividing the structure of satranidazole ( fig. 1 ) into different fragments and corresponding values of cohesive energy per mole (∆ u) and molar volume (∆ V) for each fragment was obtained from literature survey as shown in Table 2 . Solubility of satranidazole was evaluated in solvent blends containing water:dioxane for the determination of δ 2 as the varying blends of these provided a range of 10.00-23.40 (Cal/cm 3 ) 0.5 of δ 1 . The peak solubility (X 2 ) of 0.0344943 g/ml for satranidazole was observed in a solvent blend of water:dioxane (10:90) with δ 1 of 11.34 (Cal/cm 3 ) 0.5 . Thus, the solubility parameter for satranidazole can be defi ned as 11.34 (Cal/cm 3 ) 0.5 as according to the solubility measurement method; δ 2 is that value of δ 1 at which the drug exhibits maximum solubility. Table 1 lists the solvent blends, the Hildebrand solubility parameter (δ 1 ) of the solvent blends and the experimentally determined solubilities (g/ml) of satranidazole.
The molar volume method was used to determine the peak mole fraction solubility of satranidazole in various solvent blends and the mole fraction solubilities X 2 of satranidazole and Δ δ are tabulated in Table 1 . Peak mole fraction solubility was determined to be 9.6347×10 -3 in solvent blend (water:dioxane, 10:90) with δ 1 value 11.34 (Cal/ cm
, which is in agreement with the value obtained using solubility measurement method. A plot of δ 1 and X 2 (fi g. 2) showed a bell shaped curve suggesting that both at lower and higher values δ 1 = 11.34 (Cal/ cm 3 ) 0.5 the solubility of satranidazole decreased. When Δ δ was plotted against X 2 ( fig. 3) , the solubility parameter of satranidazole was confi rmed at 11.34 (Cal/cm 3 ) 0.5 as it is that value of δ 1 at which Satranidazole exhibited peak mole fraction solubility and Δ δ =0. δ 2 determined by the Fedor's group substitution method was found to be 11.3928 (Cal/ (Table 2) . Therefore, experimentally determined solubility parameter of satranidazole in water-dioxane binary solvent system was in good agreement with that of the theoretically determined solubility parameter by Molar volume method and by Fedor's group substitution method.
